Cargando…
Time of onset of atrial fibrillation and atrial fibrillation progression data from the RACE V study
AIMS: Atrial fibrillation (AF) progression is associated with adverse outcome, but the role of the circadian or diurnal pattern of AF onset remains unclear. We aim to assess the association between the time of onset of AF episodes with the clinical phenotype and AF progression in patients with self-...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227656/ https://www.ncbi.nlm.nih.gov/pubmed/36967470 http://dx.doi.org/10.1093/europace/euad058 |
_version_ | 1785050820219240448 |
---|---|
author | van de Lande, Martijn E Rama, Rajiv S Koldenhof, Tim Arita, Vicente Artola Nguyen, Bao-Oanh van Deutekom, Colinda Weberndorfer, Vanessa Crijns, Harry J G M Hemels, Martin E W Tieleman, Robert G de Melis, Mirko Schotten, Ulrich Linz, Dominik Van Gelder, Isabelle C Rienstra, Michiel |
author_facet | van de Lande, Martijn E Rama, Rajiv S Koldenhof, Tim Arita, Vicente Artola Nguyen, Bao-Oanh van Deutekom, Colinda Weberndorfer, Vanessa Crijns, Harry J G M Hemels, Martin E W Tieleman, Robert G de Melis, Mirko Schotten, Ulrich Linz, Dominik Van Gelder, Isabelle C Rienstra, Michiel |
author_sort | van de Lande, Martijn E |
collection | PubMed |
description | AIMS: Atrial fibrillation (AF) progression is associated with adverse outcome, but the role of the circadian or diurnal pattern of AF onset remains unclear. We aim to assess the association between the time of onset of AF episodes with the clinical phenotype and AF progression in patients with self-terminating AF. METHODS AND RESULTS: The Reappraisal of AF: Interaction Between Hypercoagulability, Electrical Remodelling, and Vascular Destabilization in the Progression of AF study included patients with self-terminating AF who underwent extensive phenotyping at baseline and continuous rhythm monitoring with an implantable loop recorder (ILR). In this subanalysis, ILR data were used to assess the development of AF progression and the diurnal pattern of AF onset: predominant (>80%) nocturnal AF, predominant daytime AF, or mixed AF without a predominant diurnal AF pattern. The median follow-up was 2.2 (1.6–2.8) years. The median age was 66 (59–71) years, and 117 (42%) were women. Predominant nocturnal (n = 40) and daytime (n = 43) AF onset patients had less comorbidities compared to that of mixed (n = 195) AF patients (median 2 vs. 2 vs. 3, respectively, P = 0.012). Diabetes was more common in the mixed group (12% vs. 5% vs. 0%, respectively, P = 0.031), whilst obesity was more frequent in the nocturnal group (38% vs. 12% vs. 27%, respectively, P = 0.028). Progression rates in the nocturnal vs. daytime vs. mixed groups were 5% vs. 5% vs. 24%, respectively (P = 0.013 nocturnal vs. mixed and P = 0.008 daytime vs. mixed group, respectively). CONCLUSION: In self-terminating AF, patients with either predominant nocturnal or daytime onset of AF episodes had less associated comorbidities and less AF progression compared to that of patients with mixed onset of AF. CLINICAL TRIAL REGISTRATION: NCT02726698 |
format | Online Article Text |
id | pubmed-10227656 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-102276562023-05-31 Time of onset of atrial fibrillation and atrial fibrillation progression data from the RACE V study van de Lande, Martijn E Rama, Rajiv S Koldenhof, Tim Arita, Vicente Artola Nguyen, Bao-Oanh van Deutekom, Colinda Weberndorfer, Vanessa Crijns, Harry J G M Hemels, Martin E W Tieleman, Robert G de Melis, Mirko Schotten, Ulrich Linz, Dominik Van Gelder, Isabelle C Rienstra, Michiel Europace Clinical Research AIMS: Atrial fibrillation (AF) progression is associated with adverse outcome, but the role of the circadian or diurnal pattern of AF onset remains unclear. We aim to assess the association between the time of onset of AF episodes with the clinical phenotype and AF progression in patients with self-terminating AF. METHODS AND RESULTS: The Reappraisal of AF: Interaction Between Hypercoagulability, Electrical Remodelling, and Vascular Destabilization in the Progression of AF study included patients with self-terminating AF who underwent extensive phenotyping at baseline and continuous rhythm monitoring with an implantable loop recorder (ILR). In this subanalysis, ILR data were used to assess the development of AF progression and the diurnal pattern of AF onset: predominant (>80%) nocturnal AF, predominant daytime AF, or mixed AF without a predominant diurnal AF pattern. The median follow-up was 2.2 (1.6–2.8) years. The median age was 66 (59–71) years, and 117 (42%) were women. Predominant nocturnal (n = 40) and daytime (n = 43) AF onset patients had less comorbidities compared to that of mixed (n = 195) AF patients (median 2 vs. 2 vs. 3, respectively, P = 0.012). Diabetes was more common in the mixed group (12% vs. 5% vs. 0%, respectively, P = 0.031), whilst obesity was more frequent in the nocturnal group (38% vs. 12% vs. 27%, respectively, P = 0.028). Progression rates in the nocturnal vs. daytime vs. mixed groups were 5% vs. 5% vs. 24%, respectively (P = 0.013 nocturnal vs. mixed and P = 0.008 daytime vs. mixed group, respectively). CONCLUSION: In self-terminating AF, patients with either predominant nocturnal or daytime onset of AF episodes had less associated comorbidities and less AF progression compared to that of patients with mixed onset of AF. CLINICAL TRIAL REGISTRATION: NCT02726698 Oxford University Press 2023-03-27 /pmc/articles/PMC10227656/ /pubmed/36967470 http://dx.doi.org/10.1093/europace/euad058 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Clinical Research van de Lande, Martijn E Rama, Rajiv S Koldenhof, Tim Arita, Vicente Artola Nguyen, Bao-Oanh van Deutekom, Colinda Weberndorfer, Vanessa Crijns, Harry J G M Hemels, Martin E W Tieleman, Robert G de Melis, Mirko Schotten, Ulrich Linz, Dominik Van Gelder, Isabelle C Rienstra, Michiel Time of onset of atrial fibrillation and atrial fibrillation progression data from the RACE V study |
title | Time of onset of atrial fibrillation and atrial fibrillation progression data from the RACE V study |
title_full | Time of onset of atrial fibrillation and atrial fibrillation progression data from the RACE V study |
title_fullStr | Time of onset of atrial fibrillation and atrial fibrillation progression data from the RACE V study |
title_full_unstemmed | Time of onset of atrial fibrillation and atrial fibrillation progression data from the RACE V study |
title_short | Time of onset of atrial fibrillation and atrial fibrillation progression data from the RACE V study |
title_sort | time of onset of atrial fibrillation and atrial fibrillation progression data from the race v study |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227656/ https://www.ncbi.nlm.nih.gov/pubmed/36967470 http://dx.doi.org/10.1093/europace/euad058 |
work_keys_str_mv | AT vandelandemartijne timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy AT ramarajivs timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy AT koldenhoftim timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy AT aritavicenteartola timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy AT nguyenbaooanh timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy AT vandeutekomcolinda timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy AT weberndorfervanessa timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy AT crijnsharryjgm timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy AT hemelsmartinew timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy AT tielemanrobertg timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy AT demelismirko timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy AT schottenulrich timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy AT linzdominik timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy AT vangelderisabellec timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy AT rienstramichiel timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy AT timeofonsetofatrialfibrillationandatrialfibrillationprogressiondatafromtheracevstudy |